Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pneumococcal vaccine (10-valent) is a conjugate vaccine designed to provide active immunization against invasive disease, pneumonia, and acute otitis media caused by *Streptococcus pneumoniae*. The most prominent version, Synflorix (developed by GSK), contains capsular polysaccharides from 10 specific serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F), each conjugated to a carrier protein such as non-typeable *Haemophilus influenzae* Protein D, tetanus toxoid, or diphtheria toxoid. By conjugating the polysaccharides to proteins, the vaccine induces a T-cell dependent immune response, which is effective in infants and young children. It is typically administered as a multi-dose series in the first two years of life. Another 10-valent vaccine, Pneumosil (developed by the Serum Institute of India), targets a slightly different set of serotypes (1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pneumococcal 10-valent conjugate vaccine.